Install
Rheumatology & Autoimmune
Arthritis, lupus, vasculitis, biologics, and immune‑modulating therapies.
- 3 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
- Cardiology & Metabolic Health
- Oncology & Hematology
- Neurology & Neuroscience
- Orthopedics & Sports Medicine
- Respiratory & Pulmonology
- Gastroenterology & Hepatology
- Endocrinology & Hormones
- Nephrology & Urology
- Dermatology
- OB‑GYN (Women’s Health)
- Pediatrics & Adolescent Health
- Geriatrics & Healthy Aging
- Ophthalmology & Vision
- ENT (Ear, Nose & Throat)
- Dentistry & Oral Health
Latest in Rheumatology & Autoimmune
One Health Launches Center of Excellence for Autoimmune and Inflammatory Disease
2+ day, 16+ hour ago (217+ words) NAPERVILLE, Ill., Oct. 6, 2026 /PRNewswire/ -- For people with complex autoimmune and inflammatory diseases, getting answers can sometimes take years. Patients may move from one specialist to another, repeat tests and manage multiple medications while trying to piece together what is happening to…...
Antiviral Protein IFIT1 Emerges as a Driver of Lupus Progression
11+ hour, 53+ min ago (82+ words) New research shows that the antiviral protein IFIT1 is elevated in immune cells of lupus patients, where it promotes cell death and inflammatory cytokine production, suggesting a role in disease progression. Subject of Research: The role of the interferon-stimulated gene IFIT1 in…...
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
1+ day, 3+ hour ago (164+ words) – New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD – Longer-term flare protection and safety data from the INDIGO open-label extension will be presented on October 10 at the 6th International…...
Autolus Therapeutics to Present Longer-Term Follow Up Data from CARLYSLE Trial at the American College of Rheumatology Convergence 2026
1+ day, 14+ hour ago (303+ words) Abstract: 2216Title: Obecabtagene autoleucel (obe-cel), a CD19-targeting Chimeric Antigen Receptor (CAR) T-cell Therapy, in Adults and Adolescents with Severe, Refractory Systemic Lupus Erythematosus (srSLE): Findings from the Phase I CARLYSLE StudySession date and time: Tuesday, November 10, 2026; 10:30 AM–12:30 PM ET Summary: Updated…...
Biogen's experimental lupus drug shows benefit against skin symptoms
1+ day, 5+ hour ago (48+ words) Biogen said on Friday its experimental drug showed durable improvement in skin symptoms among patients with a type of autoimmune disease in a mid-stage study. Here are some details:... Biogen's experimental lupus drug shows benefit against skin symptoms Published on…...
Biogen Inc. Announces 52-Week Results From The Phase 2 Part Of The Ongoing AMETHYST Phase 2/3 Study Of Litifilimab In Cutaneous Lupus Erythematosus
1+ day, 5+ hour ago (493+ words) Biogen Inc. announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study of litifilimab in people living with cutaneous lupus erythematosus. The updated results, presented......
Biogen's Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data from Ongoing Phase 2/3 AMETHYST Study, Reinforcing Its Potential as a First-in-Class Therapy for Cutaneous Lupus Erythematosus
1+ day, 5+ hour ago (969+ words) (Nasdaq: BIIB) announced 52-week results from the Phase 2 part of the ongoing AMETHYST Phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE). 'Access to... Biogen's Litifilimab Demonstrates Rapid and Durable Efficacy in New 52-Week Phase 2 Data…...
UCLA and Mount Sinai Begin a $4 Million NIH Study on Why Colitis Symptoms Persist After Inflammation Heals
1+ day, 20+ hour ago (731+ words) Many people with ulcerative colitis keep having stomach pain, bloating, and urgent bowel movements even after tests show their inflammation has healed. A new five-year, $4 million National Institutes of Health grant to UCLA Health and Mount Sinai will try to…...
How a Single Amino Acid Pathway May Steer Autoimmune Disease
1+ day, 18+ hour ago (70+ words) A new review in the Journal of Translational Medicine details how the glutamine-glutamate metabolic axis regulates immune cell fate and may open the door to precision metabolism-based therapies for autoimmune rheumatic diseases. Subject of Research: The role of the glutamine-glutamate…...
Lupus Research Alliance Awards $3 Million to Transform How Lupus Treatment Response is Predicted and Personalized
2+ day, 10+ hour ago (127+ words) Oct 06, 2026, 08:32 ET A global research team will analyze complex biological patterns to anticipate treatment responseand flares — advancing personalized treatments for lupus Led by Dr. Parodis, the ULTIMA project is comprised of an international team of experts, including co-primary investigators: Since…...